Drugs / CTX131
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06492304 | Aug 2024 → Mar 2026 | B-cell non-Hodgkin lymphoma, T-cell non-Hodgkin lymphoma, acute myeloid leukemia | CRISPR Therapeutics AG | Completed | No outcome recorded |
| Phase 1/2 | NCT05795595 | Mar 2023 → Sep 2025 | carcinoma of esophagus, cervical carcinoma, clear cell renal carcinoma, malignant pleural mesothelioma +1 | CRISPR Therapeutics AG | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-04 | CRISPR Therapeutics | Results CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease crisprtx.com ↗
Preliminary data from ongoing clinical trials of its next-generation candidates, CTX112 targeting CD19 and CTX131 targeting CD70, suggest that these candidates may improve upon that clinical profile. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-04 | CRISPR Therapeutics | CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease crisprtx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06492304 ↗ |
| Modality | Cell therapy | “allogeneic T cells” NCT05795595 ↗ |
| Route | Intravenous | “Administered by IV infusion” NCT05795595 ↗ |
| Target | CD70 | “CD70-directed T-cell immunotherapy” NCT05795595 ↗ |